-
2
-
-
33750603100
-
Changing epidemiology of small cell lung cancer in the United States over the last 30 years: Analysis of the surveillance, epidemiologic and end results database
-
Govindan R, Page N, et al. Changing epidemiology of small cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic and end results database. J Clin Oncol 2006; 24: 4539-4544.
-
(2006)
J Clin Oncol
, vol.24
, pp. 4539-4544
-
-
Govindan, R.1
Page, N.2
-
3
-
-
0030912190
-
Revisions in the international system for staging lung cancer
-
Mountain C. Revisions in the international system for staging lung cancer. Chest 1997; 111: 1710-1717.
-
(1997)
Chest
, vol.111
, pp. 1710-1717
-
-
Mountain, C.1
-
4
-
-
34848849863
-
Treatment of nonsmall cell lung cancer: Stage IV: ACCP evidence-based clinical practice guidelines
-
(2nd Edition)
-
Socinski MA, Crowell R, Hensing TE, et al. Treatment of nonsmall cell lung cancer: stage IV: ACCP evidence-based clinical practice guidelines (2nd Edition). Chest; 132 (suppl. 3): 277S-289S.
-
Chest
, vol.132
, Issue.SUPPL. 3
-
-
Socinski, M.A.1
Crowell, R.2
Hensing, T.E.3
-
5
-
-
66549109768
-
Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up
-
D'Addario G, Felip E. Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009; 20 (suppl. 4): iv68-iv70.
-
(2009)
Ann Oncol
, vol.20
, Issue.SUPPL. 4
-
-
D'Addario, G.1
Felip, E.2
-
6
-
-
74949133978
-
American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer
-
Azzoli CG, Baker S Jr, Temin S, et al. American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2009; 27: 6251-6266.
-
(2009)
J Clin Oncol
, vol.27
, pp. 6251-6266
-
-
Azzoli, C.G.1
Baker Jr., S.2
Temin, S.3
-
7
-
-
84860537353
-
Maintenance treatment of advanced non-small-cell lung cancer: Results of an international expert panel meeting of the Italian association of thoracic oncology
-
Gridelli C, De Marinis F, Di Maio M, et al. Maintenance treatment of advanced non-small-cell lung cancer: results of an international expert panel meeting of the Italian association of thoracic oncology. Lung Cancer 2012; 76: 269-279.
-
(2012)
Lung Cancer
, vol.76
, pp. 269-279
-
-
Gridelli, C.1
De Marinis, F.2
Di Maio, M.3
-
8
-
-
70350225538
-
Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: A randomised, doubleblind, phase 3 study
-
Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, doubleblind, phase 3 study. Lancet 2009; 374: 1432-1440.
-
(2009)
Lancet
, vol.374
, pp. 1432-1440
-
-
Ciuleanu, T.1
Brodowicz, T.2
Zielinski, C.3
-
9
-
-
64049115311
-
The differential efficacy of pemetrexed according to NSCLC histology: A review of two phase III studies
-
Scagliotti G, Hanna N, Fossella F, et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two phase III studies. Oncologist 2009; 14: 253-263.
-
(2009)
Oncologist
, vol.14
, pp. 253-263
-
-
Scagliotti, G.1
Hanna, N.2
Fossella, F.3
-
10
-
-
84862781680
-
Quality of life in patients with advanced non-small-cell lung cancer given maintenance treatment with pemetrexed versus placebo (H3E-MCJMEN): Results from a randomised, double-blind, phase 3 study
-
Belani CP, Brodowicz T, Ciuleanu TE, et al. Quality of life in patients with advanced non-small-cell lung cancer given maintenance treatment with pemetrexed versus placebo (H3E-MCJMEN): results from a randomised, double-blind, phase 3 study. Lancet Oncol 2012; 13: 292-299.
-
(2012)
Lancet Oncol
, vol.13
, pp. 292-299
-
-
Belani, C.P.1
Brodowicz, T.2
Ciuleanu, T.E.3
-
11
-
-
77953541527
-
Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: A multicentre, randomised, placebo-controlled phase 3 study
-
Cappuzzo F, Ciuleanu T, Stelmakh L, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010; 11: 521-529.
-
(2010)
Lancet Oncol
, vol.11
, pp. 521-529
-
-
Cappuzzo, F.1
Ciuleanu, T.2
Stelmakh, L.3
-
12
-
-
25844468887
-
-
Accessed: April 25, European Medicine Agency, Summary of opinion (post authorisation): Tarceva. Available at
-
European Medicine Agency. Committee for medicinal products for human use (CHMP). Summary of opinion (post authorisation): Tarceva. Available at http://www.ema.europa.eu/pdfs/human/opinion/TarcevaII_8608010en.pdf Accessed: April 25, 2010.
-
(2010)
Committee for medicinal products for human use (CHMP)
-
-
-
13
-
-
84859787320
-
-
Accessed: April 25, Food and Drug Administration, Available at
-
Food and Drug Administration. Highlights of prescribing information: Tarceva. Available at http://www.accessdata.fda.gov/drugsatfda_ docs/label/2010/021743s14s16lbl.pdf Accessed: April 25, 2010.
-
(2010)
Highlights of prescribing information: Tarceva
-
-
-
14
-
-
84857507055
-
Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): A double-blind, phase 3, randomised controlled trial
-
Paz-Ares L, De Marinis F, Dediu M, et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol 2012; 13: 247-255.
-
(2012)
Lancet Oncol
, vol.13
, pp. 247-255
-
-
Paz-Ares, L.1
De Marinis, F.2
Dediu, M.3
-
15
-
-
84867566940
-
PARAMOUNT: Final overall survival (OS) results of the phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo (plb) plus BSC immediately following induction treatment with pem plus cisplatin (cis) for advanced nonsquamous (NS) non-small cell lung cancer (NSCLC)
-
abstr LBA7507
-
Paz-Ares L, De Marinis F, Dediu M, et al. PARAMOUNT: Final overall survival (OS) results of the phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo (plb) plus BSC immediately following induction treatment with pem plus cisplatin (cis) for advanced nonsquamous (NS) non-small cell lung cancer (NSCLC). J Clin Oncol 2012; 30: suppl abstr LBA7507.
-
(2012)
J Clin Oncol
, vol.30
, Issue.SUPPL.
-
-
Paz-Ares, L.1
De Marinis, F.2
Dediu, M.3
-
16
-
-
84862797797
-
Safety, resource use, and quality of life results from PARAMOUNT: A phase III study of maintenance pemetrexed plus best supportive care versus placebo plus best supportive care immediately following induction treatment with pemetrexed-cisplatin for advanced nonsquamous nonsmall cell lung cancer
-
(14 World Conference on Lung Cancer-Amsterdam, July 3-7, 2011)
-
Gridelli C, De Marinis F, Pujol JL, et al. Safety, resource use, and quality of life results from PARAMOUNT: a phase III study of maintenance pemetrexed plus best supportive care versus placebo plus best supportive care immediately following induction treatment with pemetrexed-cisplatin for advanced nonsquamous nonsmall cell lung cancer. J Thorac Oncol 2011; 6 (suppl 6): S323 (14 World Conference on Lung Cancer-Amsterdam, July 3-7, 2011).
-
(2011)
J Thorac Oncol
, vol.6
, Issue.SUPPL. 6
-
-
Gridelli, C.1
De Marinis, F.2
Pujol, J.L.3
-
17
-
-
80053639884
-
2011 focused update of 2009 American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer
-
Azzoli CG, Temin S, Aliff T, et al. 2011 focused update of 2009 American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2011; 29: 3825-31.
-
(2011)
J Clin Oncol
, vol.29
, pp. 3825-3831
-
-
Azzoli, C.G.1
Temin, S.2
Aliff, T.3
-
18
-
-
84857502282
-
Maintenance chemotherapy in advanced non-small cell lung cancer
-
Jassem J. Maintenance chemotherapy in advanced non-small cell lung cancer. Lancet Oncol 2012; 13: 217-218.
-
(2012)
Lancet Oncol
, vol.13
, pp. 217-218
-
-
Jassem, J.1
-
19
-
-
77955097091
-
Cost-effectiveness of pemetrexed as first-line maintenance therapy for advanced nonsquamous non-small cell lung cancer
-
Klein R, Wielage R, Muehlenbein C, et al. Cost-effectiveness of pemetrexed as first-line maintenance therapy for advanced nonsquamous non-small cell lung cancer. J Thorac Oncol 2010; 5: 1263-72.
-
(2010)
J Thorac Oncol
, vol.5
, pp. 1263-1272
-
-
Klein, R.1
Wielage, R.2
Muehlenbein, C.3
|